Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
Document Type
Article
Publication Date
11-22-2022
Publication Title
JAMA
Abstract
This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.
Volume
328
Issue
20
First Page
2062
Last Page
2064
Recommended Citation
Cohen SH, Louie TJ, Sims M, Wang EEL, Memisoglu A, McGovern BH, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial. JAMA. 2022 Nov 22;328(20):2062-2064. doi: 10.1001/jama.2022.16476. PMID: 36260754.
DOI
10.1001/jama.2022.16476
ISSN
1538-3598
PubMed ID
36260754
COinS